CorMedix (CRMD) Reiterated at Market Outperform by Citizens on Positive REZZAYO Results
Tweet Send to a Friend
Citizens analyst Jason N. Butler reiterated a Market Outperform rating and $19.00 price target on CorMedix (NASDAQ: CRMD).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
